Genetic Vaccines and Therapy · 2004 · 40 citations · 20 references
Life SciencesInfectious DiseasesMolecular BiologyGene DeliveryMolecular VirologyVirologyNucleic Acid DeliveryNucleic Acid VaccinesRna InterferenceSmall Interfering Rna DeliveryViral InfectionsViral VaccinesAdeno-associated Viral VectorsDendritic Cell Antiviral ResponsesDengue FeverDengue Hemorrhagic FeverDengue VaccinesRna Delivery SystemsViral Vector DeliveryVirally Derived Delivery Vectors
BACKGROUND: The need for safe and effective treatment of dengue virus (DEN), a class A agent that causes dengue hemorrhagic fever/dengue shock syndrome, has been a critical global priority. An effective vaccine for DEN is not yet available. In this study the possibility of attenuating DEN infection using adeno-associated virus (AAV)-encoded short interfering RNAs (siRNA) was examined in Vero cells and human dendritic cells (DCs). METHODS: A cassette encoding siRNA targeted to a 3' untranslated sequence common to all DEN serotypes was designed and tested for its ability to attenuate DEN infection by use of AAV delivery. RESULTS: Vero cells or DCs infected with AAV-siRNA showed a significant, dose-dependent reduction in DEN infection. Treatment of DCs with AAV-siRNA also decreased the DEN-induced apoptosis of DCs and did not induce significant inflammation. CONCLUSION: These results demonstrate that AAV-mediated siRNA delivery is capable of reducing DEN infection in cells and may be useful in decreasing DEN replication in humans.
20
Argonaute2, a Link Between Genetic and Biochemical Analyses of RNAi
Scott M. Hammond, Sabrina Boettcher, Amy A. Caudy et al. · Science · 2001 · 1.5K citations
Human skin Langerhans cells are targets of dengue virus infection
Shuenn-Jue L. Wu, Géraldine Grouard-Vogel, Wellington Sun et al. · Nature Medicine · 2000 · 671 citations
Ribonuclease activity and RNA binding of recombinant human Dicer
Patrick Provost · The EMBO Journal · 2002 · 451 citations · Full text